IGF-1
Insulin-like growth factor 1 is an endogenous peptide hormone and the active sequence used in recombinant medicines such as mecasermin. It is distinct from IGF-1 LR3, IGF-1 DES, growth hormone, and products that merely change endogenous IGF-1 concentrations.
Pharmacokinetic model
A route-level PK model for igf-1 is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Peptide Medicine
- Suggested cadence
- once daily
Research behind this entry
-
The influence of vitamin D supplementation on IGF-1 levels in humans: a systematic review and meta-analysis
Meta-analysis of eight randomized trials found no statistically significant overall change in circulating IGF-1 with vitamin D supplementation. This is indirect biomarker evidence and does not study administration,…
-
Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency
Direct human SC rhIGF-1 study reported about seven-hour time to peak and roughly 20-hour half-life in healthy volunteers, but about six-hour half-life in growth-hormone-receptor deficiency. That population difference is…
-
Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
This citation reports a human clinical study involving IGF-1. It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.
3 published studies referenced in the app, each with a plain-language summary.